Kornimate/medical-research-clean huggingface dataset:
reliability and validity of urdu version of mini-bestest in persons with parkinson's disease

Conditions: Balance

Summary: various clinical scales are available to investigate balance impairment, mini-bestest is one of them. thus, this study aims to translate the mini-bestest into urdu and investigate its psychometric properties in the pakistani parkinson's population with dynamic balance impairment.

the aim of study is to translate and culturally adapt mini-bestest into urdu language and secondly to investigate the reliability and validity of urdu version of mini-bestest in parkinson's pakistani population. this study will be cross sectional survey study in which convenience sampling technique will be used. the results of study will help to know the validity and reliability of mini-bestest in urdu version with dynamic balance impairments in parkinson's population. the reliability of the scale will be checked through internal consistency and test-retest methods. internal consistency will be analyzed with cronbach's alpha value. test-retest reliability will be assessed using an intraclass correlation coefficient with 80 patients.

Eligibility criteria:
inclusion criteria: 1. all persons with parkinson disease and ability to follow commands were included in the study. 2. living independently in the community 3. able to walk 6 m independently 4. willing to participate in the study. exclusion criteria: 1. history of other neurological disorders 2. musculoskeletal damage which affects walking ability 3. presence of serious medical condition 4. history of surgical treatments for parkinson disease 5. not willing to participate in the study 6. history of faint, vertigo, dizziness,or taking medications which can cause dizziness 7. history of any medical condition which can affect balance.

Keywords: balance; mini-bestest; parkinson's ; reliability; validity
local anesthesia and analgesics in endodontic pain

Conditions: Odontalgia

Summary: for patients with a toothache, is pain relief after root canal procedure improved using long acting local anesthetic and analgesics? the purpose of this clinical trial is the investigate the effect of long acting local anesthetic with 1 of 4 oral medication groups, on post-operative endodontic pain.

patients (n=220) presenting to the university of minnesota endodontic clinic, with moderate to severe pain from toothache requiring root canal treatment ,will be invited to participate in the study. the endodontic treatment is not part of the research. patients will complete pain evaluation forms and take 2 doses of prescribed medication. normally after a root canal procedure, patients will be suggested to take over-the-counter ibuprofen if needed, or prescribed an analgesic if they are having severe pain. we will be randomizing patients in double blind manner to receive regular or long acting local anesthesia and post-op medications (placebo or 1 of 3 analgesics), with the patient evaluating their pain before starting root canal (pre-treatment pain), after root canal, after analgesics and during the following day.

Eligibility criteria:
inclusion criteria: 18-65 y.o. american society of anesthesiologists physical classification i or ii can understand and complete pain evaluation forms tooth pain (\>3 out of 10) needing root canal ability to read and provide informed consent must be able to swallow tablets exclusion criteria: allergy/intolerance to analgesics (ibuprofen, naproxen, vicodin) patients who are pregnant patients currently on pain medications for an unrelated condition patients unwilling to fill out pain scales liver or kidney disease unable to understand and complete consent form and pain evaluation forms -

Keywords: endodontic treatment, analgesics, anesthesia, post-operative pain
sleep & postoperative delirium in hispanic/ latino patients after cardiothoracic surgery

Conditions: Delirium in Old Age; Sleep Disturbance; Circadian Rhythm Sleep Disorder

Summary: the purpose of this research is to study pre-operative sleep problems and delirium in hispanic/latino patients after heart and lung surgery.


Eligibility criteria:
inclusion criteria: 1. self identify as hispanic/latino or preferred language as spanish 2. undergoing scheduled elective and urgent cardiothoracic surgery 3. 50 years of age and older exclusion criteria: 1. inability to consent 2. preferred language other than english, spanish or portuguese 3. emergency surgery 4. anticipated discharge \< 48 hours 5. individuals \< 50 years of age 6. pregnant women 7. prisoners
neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a predictor factors for chronic kidney disease progression

Conditions: CKD

Summary: in this study, we aim to investigate whether nlr and plr levels are associated with decline of kidney function in patients with ckd.

chronic inflammation is closely associated with various chronic diseases, such as diabetes mellitus, cardiovascular disease, and chronic kidney disease (ckd) (1). patients with ckd tend to have elevated levels of inflammatory mediators, including high-sensitivity c-reactive protein (hs-crp), tumor necrosis factor alpha (tnf alpha), and interleukin (il)-6 (2).these mediators stimulate inflammatory pathway, leading to glomerular hypertension, tubulointerstitial fibrosis, kidney scarring, and, finally, ckd progression and increased cardiovascular events (3,4). therefore, it is important to evaluate and decrease the extent of chronic inflammation in patients with ckd. patients with ckd have higher levels of proinflammatory cytokines, but it remains unclear which biomarker is the best indicator of inflammation in patients with ckd. the neutrophil-to-lymphocyte ratio (nlr), obtained by dividing the absolute number of neutrophils to the lymphocyte count, is increasingly studied as a new inflammatory marker. an elevated nlr has recently been reported to be an independent predictor of mortality in patients with cardiovascular disease or cancer \[5-8\]. as ckd is a chronic inflammatory disease, high nlr can predict ckd progression, cardiovascular disease and cancer. however, significantly few studies have investigated the association between high nlr and ckd progression \[9-12\]. platelet-to-lymphocyte ratio (plr) has recently been recognized as a novel inflammatory marker and has been shown to be associated with the prognosis in ckd patients \[13\]. in 2012, kidney disease: improving global outcome (kdigo) classified ckd in six categories by gfr estimation (in ml/min/1.73 m2).

Eligibility criteria:
inclusion criteria: * 200 patients diagnosed with ckd and their age range between 18-65 years old who will be admitted at auh. exclusion criteria: 1. pediatric patients aged below\< 18 or elderly patients aged above 65. 2. pregnant females. 3. patients with diabetes mellitus. 4. acute kidney injury (aki). 5. patients with current infections. 6. patients who have any type of malignancy. 7. patients who have any type of multi-organ failure. 8. ckd patients on dialysis

Keywords: nlr &amp; plr in ckd
natural history study in subjects with usher syndrome

Conditions: Usher Syndrome, Type 1B

Summary: natural history study in subjects with usher syndrome ((ush1b) is a multi-centre, longitudinal, observational study designed to evaluate disease progression in subjects with ush1b by several vision-related assessments.

natural history study in subjects with usher syndrome (ush1b) is being conducted to understand the progression of disease in ush1b patients as measured by visual acuity and visual field testing and a number of other vision-related assessments. disease progression will be evaluated as change over time in these measures and associations between the endpoints will be examined. the primary objective of this study is to evaluate the natural progression of disease over time in ushib patients using visual field testing and best corrected visual acuity. the secondary objectives of this study are to evaluate the progression of disease over time in ushib patients through additional assessments: * microperimetry (only in selected centres) * fundus autofluorescence (faf) * optical coherence tomography (oct) * full-field electroretinogram (erg), * multifocal electroretinogram, * vision-related function and quality of life, as measured by the 25-item national eye institute visual function questionnaire (nei vfq-25)

Eligibility criteria:
inclusion criteria: 1. must be willing to adhere to protocol for long-term follow-up as evidenced by written informed consent or parental permission and subject assent. 2. subjects diagnosed with ush1. 3. molecular diagnosis of ush1b due to myo7a mutations (homozygotes or compound heterozygotes). 4. age eight years old or older at the time of baseline. 5. visual acuity ≥ 20/640 in at least one eye exclusion criteria: 1. unable or unwilling to meet requirements of the study. 2. unable to communicate with suitable verbal/auditory and/or tactile sign language (in the opinion of the investigator) 3. participation in a clinical study with an investigational drug in the past six months. 4. pre-existing eye conditions that would interfere with the interpretation of study endpoints (for example, glaucoma, corneal or significant lenticular opacities, cystoid macular oedema, macular hole). 5. complicating systemic diseases in which the disease itself, or the treatment for the disease, can alter ocular function. examples are malignancies whose treatment could affect central nervous system function (for example, radiation treatment of the orbit; leukemia with cns/optic nerve involvement). also excluded would be subjects with immuno- compromising diseases, as there could be susceptibility to opportunistic infection \[such as cytomegalovirus (cmv) retinitis\]. 6. subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g. macular edema or proliferative changes). 7. prior ocular surgery within three months. 8. any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study.
genetic variants and postoperative pain

Conditions: Postoperative Pain; Analgesia; Surgical Procedure, Operative

Summary: prospective observational study to analyse patients' pain related outcome after surgery and ist association to genetic variants and non-genetic variables.

background severe acute pain as well as long-lasting pain after surgery and pain-related interference of daily activities are frequent. some risk factors for severe pain after surgery in adults have been described, e.g. younger age and pre-existing chronic pain. the question arises whether a specific genetic background is related to an unfavorable pain outcome. objective the aim of this study is to investigate clinical and genetic variables and their possible association to severe acute postoperative pain, higher analgesic consumption and the development of chronic postsurgical pain. methods prospective observational study investigating clinical, patient related, surgery related and anesthesia related variables as well as genetic variants and their possible association to patients' pain related outcome after surgery.

Eligibility criteria:
inclusion criteria: * 18 years and older * written informed consent * elective surgery * patients' ability to understand the purpose of the study exclusion criteria * no informed consent * cognitive impairment

Keywords: postoperative pain analgesics patient reported outcome pain related impairment genetic association study
docetaxel and epirubicin in advanced gastric cancer

Conditions: Stomach Neoplasms

Summary: 1.study rationale:there is no standard regimen for the advanced and/or metastatic gastric cancer patients who relapsed after adjuvant chemotherapy or failed to first systemic chemotherapy. 2.primary objectives:to evaluate overall response rate according to the response evaluation criteria in solid tumors criteria and to investigate time to response 3.design:single-center, open label, phase ii study. docetaxel 75mg/m2 administered on day 1 as intravenously combined with intravenous epirubicin 60mg/m2 given day 2 every 3 weeks. 4.primary endpoints: 1. efficacy:overall response rate according to the response evaluation criteria in solid tumors criteria, time to response, duration of response, and time to treatment failure. 2. safety-adverse events and laboratory tests, graded according to the nci common toxicity criteria for adverse effects (version 3.0).


Eligibility criteria:
inclusion criteria: * male and female outpatients ≥ 18 years, * eastern cooperative oncology group performance status below 1, with histologically confirmed as gastric adenocarcinoma with inoperable and/or metastatic disease. * patients must have at least one target lesion with a minimum lesion size as per the response evaluation criteria in solid tumors criteria (at least 1 unidimensional measurable lesion ≥ 20 mm in diameter by conventional ct or mri scan, or ≥ 10 mm in diameter by spiral ct scan). * creatinine clearance ≥ 60ml/min (estimated creatinine clearance must be calculated at baseline for all patients.) * adequate major organ function : - hematopoietic function: white blood cell \>4,000/mm3 or absolute neutrophil count \> 2,000/mm3, platelet count ≥ 100,000/mm3,- hepatic function: bilirubin \< 1.5 x upper normal limit, aspartate aminotransferase/alanine aminotransferase levels \<2.5 x upper normal limit, alkaline phosphatase \< 5 x upper normal limit (except in case of bone metastasis without any liver disease) - renal function: creatinine \<1 x upper normal limit or creatinine clearance ≥ 60ml/min. exclusion criteria: * patients must not have previously received systemic treatment (cytotoxic chemotherapy or active/passive immunotherapy) for advanced or metastatic disease. * adjuvant or neo-adjuvant treatment for non-metastatic (m0) disease is allowed if completed at least 6 months prior to initiation of study treatment. * the following laboratory values: - neutrophils ≤1.5 x 109 /l, platelet count\<100 x 109 /l- serum bilirubin ≥ 1.5 x upper normal limit, aspartate aminotransferase , alanine aminotransferase \> 2.5 x upper normal limit or \> 5 x upper normal limit in the case of liver metastases- alkaline phosphatase \> 2.5 x upper normal limit or 5 x upper normal limit in the case of liver metastases or \> 10 x upper normal limit in the case of bone disease. * prior therapy with taxotere or epirubicin is excluded.
a phase 2 study of jaktinib in participants with moderate to severe psoriasis

Conditions: Moderate-to-Severe Plaque Psoriasis

Summary: this is study designed to investigate the efficacy and safety of jaktinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the psoriasis area and severity index (pasi) score and routine safety assessments.


Eligibility criteria:
inclusion criteria: * 18\~65 years old (including lower limit), no gender limit； * you must have active chronic plaque psoriasis for at least 6 months prior to entry into the study； * you must have active plaque psoriasis covering at least 10% body surface area； you must have psoriasis area and severity index (pasi) score of at least 12；you must have static physician's global assessment (spga) score of at least 3； * the patient can communicate well with the investigator and follow the research and follow-up procedures； * understand and voluntarily sign the informed consent form. exclusion criteria: * you must not have prior treatment with an oral janus kinase (jak) inhibitor； * you must not have received a phototherapy within 4 weeks prior to entry into the study； * you must not have a history of active hepatitis b, hepatitis c, or human immunodeficiency virus (hiv)； * you must not have a history of chronic alcohol abuse or intravenous (iv) drug abuse
the adjunctive effect of probiotics to non surgical treatment of chronic periodontitis

Conditions: Chronic Periodontitis

Summary: evaluation of clinical and microbiological effect of lactobacillus reuteri probiotics.

the present randomized controlled clinical trial was conducted to evaluate the effects of lactobacillus reuteri-containing probiotic suspension as an adjunct to scaling and root planing (srp). material and methods: twenty sites from twelve chronic periodontitis patients were recruited and monitored clinically and microbiologically at baseline, three, and six months after therapy for plaque index (pi), bleeding on probing (bop), probing pocket depth (ppd) and clinical attachment level (cal) and microbiologically or porphyromonas gingivalis (p. gingivalis) load. patients meeting the inclusion criteria were scheduled within one week for two sessions of srp performed using ultrasonic scalers and hand instrumentation. after srp, oral hygiene measures were reassured and then sites were randomly allocated to one of the two groups 10 sites each. group i (srp only) and group ii (srp + probiotic). group ii received srp and sub-gingival delivery of 1ml of probiotic l. reuteri suspension at baseline (immediately after srp), one, two and four weeks using blunt syringe. periodontal dressing was applied after placement of the drug.

Eligibility criteria:
inclusion criteria: 1. patients with good systemic health. 2. patients with moderate chronic periodontitis with attachment level ranging from 3-4 mm. 3. optimal compliance as evidenced by no missed treatment appointments and positive attitude towards oral hygiene. 4. no gingival recession. exclusion criteria: 1. patients with history of antibiotic, anti-inflammatory drugs or periodontal therapy in the preceding 6 months. 2. patients with risk factors (e.g. - smoking, uncontrolled diabetes, uncontrolled hypertension, pregnant or any other systemic disease which can alter the course of periodontal therapy). 3. patients who are allergic to lactate products.

Keywords: chronic periodontitis
therapeutic effect and safety study of decitabine in elderly acute myeloid leukemia patients

Conditions: Untreated Adult Acute Myeloid Leukemia; Effect of Drugs; Drug Safety

Summary: the purpose of this study is to confirm the safety and the therapeutic effect of decitabine in the treatment of elderly acute myeloid leukemia (aml) patients.

the outcome of the elderly aml patients is very poor. no obvious progress was achieved in this field. decitabine is a kind of specific dna methylation shift enzyme inhibitor. it can reverse the dna methylation and induce the differentiation and apoptosis of the tumor cells. recent studies about decitabine in the treatment for elderly aml patients had achieved inspiring results and indicated that low dose decitabine maybe a good choice for elderly aml patients. so in this research the investigators plan to evaluate the safety and the therapeutic effect of decitabine in the treatment of elderly aml patients.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of acute myeloid leukemia.de novo or secondary aml. 2. age \>= 60years,female and male. 3. before the enrollment，wbc \ 20×10e9/l（hydroxyurea is permitted.） 4. in 2 weeks before the enrollment，total bilirubin \< 1.5×uln，alt \< 2.5×uln；ggt \< 2.5×uln ，scr \< 2.0×uln or creatinine clearance rate ≥ 50 ml/min（cockroft-gault）. 5. before the enrollment，patients must be free from the toxicity caused by the former treatment.received no chemotherapy in the last 4 weeks and no nitrosourea in the last 6 weeks. 6. contraception must be taken to avoid pregnancy during the study. 7. ecog 0,1, or 2, predicted lifetime longer than 12 weeks. 8. patients must sign the informed consent prior to any study related screening procedures being performed. exclusion criteria: 1. acute promyelocytic leukemia. 2. chromosome and genetic abnormalities related with t（8; 21）、inv（16）、t（15; 17）. 3. central nervous system leukemia. 4. bone marrow dry tap. 5. patients received stem cell transplantation or chemotherapy containing azacitidine,cytarabine or decitabine in last one year, radiation therapy in last 14 days,lenalidomide in 30 days before included. 6. patients suffered from autoimmune hemolytic anemia or immune thrombocytopenia. 7. patients suffered from non-leukemia related comorbidities that will cause dysfunction of organs. 8. patients suffered from unstable angina or （nyha）3/4 congestive heart failure. 9. patients suffered from chronic respiratory disease and needed continued oxygen. 10. other active malignancy. 11. active hbv,hcv or aids patients. 12. uncontrolled virus or bacterium infection. 13. the investigator believe that patients who are not suitable for this trial. 14. severe mental or body disorders which will interfere the research such as uncontrolled heart,lung diseases,diabetes,etc. 15. allergic to decitabine or its accessory. 16. patients received other researches in last 30 days. 17. without contraception. 18. complications causing organ dysfunction which are not caused by aml.

Keywords: decitabine acute myeloid leukemia elderly patient
tranexamic acid reduce blood loss in meningioma resection

Conditions: Meningioma

Summary: in neurosurgical setting, a large sample size trials of tranexamic acid (txa) has been limited to tbi and sah. the evidence of txa in brain tumor was scarce. a few case reports support the role of txa in brain tumor patients with significant intraoperative bleeding and difficult achieving hemostasis. to prove the benefit of txa for an attenuation of blood loss in brain tumor patients, research with a larger sample size is required. this prospective, randomized double-blind controlled study will be conducted to evaluate the effect of txa in reducing blood loss and blood transfusion in patients with intracranial meningiomas, diameter \> 5 cm in at least 2 dimensions from the latest radiographic findings.

background and literature review: 1. meningioma 2. coagulation in craniotomy to remove meningioma 3. bleeding in craniotomy to remove meningioma 4. tranexamic acid (txa) 5. knowledge gap the topics shown above has been reviewed to conduct a prospective randomized double-blind, placebo controlled study. to prove the study hypothesis: will intraoperative txa administration in adult patients scheduled for craniotomy to remove large meningioma decrease blood loss?

Eligibility criteria:
inclusion criteria: * the patients whose aged 18 to 60 years * the patients who was diagnosed intracranial meningioma * the radio-graphic finding of tumor diameter \> 5 cm in at least 2 dimensions * the patients have written informed consent * the patients is scheduled for elective craniotomy to remove tumor exclusion criteria: * patients who refuse to participate in this study * patients with recurrent tumor * the patient is set operation for intracranial tissue biopsy * the patients with history of txa allergy * the pregnant patients * the patients with history of significant thromboembolic episode * the patients with significant renal dysfunction (gfr ≤ 50 ml/min)

Keywords: tranexamic acid meningioma blood loss